HAE:NYE-Haemonetics Corporation

EQUITY | Medical Instruments & Equipment | New York Stock Exchange

Last Closing Price

USD 86.17

Change

+0.16 (+0.19)%

Market Cap

USD 4.39B

Volume

0.44M

Average Target Price

USD 119.50 (+38.68%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Haemonetics Corp is a health care company.It provides products to customers involved in the processing,handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes & reduce costs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-02-14 )

Largest Industry Peers for Medical Instruments & Equipment

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.54 (-0.22%)

USD 65.93B
BAX Baxter International Inc.

-0.23 (-0.32%)

USD 38.67B
BCR C.R. Bard Inc.

N/A

USD 24.14B
RMD ResMed Inc.

+0.51 (+0.52%)

USD 14.18B
COO The Cooper Companies Inc.

-1.99 (-0.72%)

USD 13.72B
TFX Teleflex Incorporated

-0.06 (-0.02%)

USD 12.95B
VAR Varian Medical Systems Inc.

-0.95 (-0.72%)

USD 12.05B
STE STERIS plc

+0.85 (+0.71%)

USD 10.17B
WST West Pharmaceutical Services I..

-4.94 (-4.67%)

USD 7.84B
HRC Hill-Rom Holdings Inc

+0.07 (+0.07%)

USD 6.90B

ETFs Containing HAE

Symbol Name Weight Mer Price(Change) Market Cap
VTWG Vanguard Russell 2000 Gro.. 0.56 % 0.20 %

+0.47 (+0.33%)

USD 0.28B
IWO iShares Russell 2000 Grow.. 0.51 % 0.24 %

+0.74 (+0.38%)

USD 9.09B
VTWO Vanguard Russell 2000 Ind.. 0.29 % 0.15 %

+0.20 (+0.16%)

USD 1.55B
IWM iShares Russell 2000 0.26 % 0.20 %

+0.35 (+0.23%)

USD 43.46B
GSSC GS ActiveBeta U.S. Small .. 0.25 % 0.20 %

+0.07 (+0.15%)

USD 0.09B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Equipment)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.87% 7% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.87% 7% F 2% F
Trailing 12 Months  
Capital Gain 23.77% 77% C+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.77% 77% C+ 91% A-
Trailing 5 Years  
Capital Gain 124.69% 70% C- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.69% 50% F 94% A
Average Annual (5 Year Horizon)  
Capital Gain 35.20% 100% A+ 97% A+
Dividend Return 35.20% 100% A+ 97% A+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.77% 15% F 6% F
Risk Adjusted Return 70.72% 31% F 71% C-
Market Capitalization 2.01B 31% F 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Equipment)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 96.82 23% F 4% F
Price/Book Ratio 6.35 31% F 10% F
Price / Cash Flow Ratio 5.78 62% D- 18% F
Price/Free Cash Flow Ratio 61.99 15% F 7% F
Management Effectiveness  
Return on Equity 6.65% 38% F 44% F
Return on Invested Capital 7.75% 31% F 45% F
Return on Assets 3.71% 38% F 59% F
Debt to Equity Ratio 47.00% 42% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector